Ogestrel 0.5/50-28 side effects by duration, gender and age - a phase IV clinical study of FDA data

< 1 month:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

1 - 6 months:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

1. Abdominal distension

5 - 10 years:

n/a

10+ years:

n/a

not specified:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
2. Abdominal distension
3. Cholecystitis (infection of gallbladder)
4. Haematochezia (passage of stools containing blood)
5. Injection site haemorrhage (bleeding from injection site)

female:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
2. Abdominal distension
3. Cholecystitis (infection of gallbladder)
4. Haematochezia (passage of stools containing blood)
5. Injection site haemorrhage (bleeding from injection site)

male:

n/a

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

30-39:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

40-49:

1. Abdominal distension
2. Cholecystitis (infection of gallbladder)
3. Injection site haemorrhage (bleeding from injection site)

50-59:

1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

60+:

n/a